Rhenman & Partners Asset Management AB Has $14.45 Million Stock Holdings in Insulet Corporation $PODD

Rhenman & Partners Asset Management AB reduced its stake in Insulet Corporation by 24.6% in Q2, owning 46,000 shares worth $14.45 million. Insulet is the fund's 21st largest holding, comprising 1.8% of its portfolio. Other investors like American Century Companies and Vanguard Group have increased their holdings. Insulet's stock performance is strong, with a market cap of $23.13 billion and recent earnings surpassing expectations.

Rhenman & Partners Asset Management AB lowered its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 24.6% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 46,000 shares of the medical instruments supplier's stock after selling 15,000 shares during the period. Insulet makes up 1.8% of Rhenman & Partners Asset Management AB's portfolio, making the stock its 21st largest holding. Rhenman & Partners Asset Management AB owned 0.07% of Insulet worth $14,452,000 as of its most recent filing with the SEC.

3 Medical Technology Stocks Outperforming in 2025

Several other large investors have also recently bought and sold shares of the stock. American Century Companies Inc. boosted its holdings in shares of Insulet by 34.8% during the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock worth $302,686,000 after acquiring an additional 297,734 shares during the period. Nuveen LLC acquired a new stake in Insulet during the 1st quarter worth approximately $74,163,000. Kayne Anderson Rudnick Investment Management LLC lifted its holdings in Insulet by 1,316.5% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier's stock worth $50,818,000 after purchasing an additional 179,850 shares during the last quarter. Vanguard Group Inc. boosted its stake in Insulet by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock valued at $2,276,553,000 after purchasing an additional 178,976 shares during the period. Finally, AustralianSuper Pty Ltd lifted its holdings in shares of Insulet by 487.5% during the second quarter. AustralianSuper Pty Ltd now owns 205,168 shares of the medical instruments supplier's stock worth $64,460,000 after buying an additional 170,247 shares in the last quarter.

Insider Transactions at Insulet

In related news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the company's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares of the company's stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.39% of the company's stock.

Insulet Stock Performance

Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer

NASDAQ PODD opened at $328.85 on Wednesday. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $354.88. The firm has a market capitalization of $23.13 billion, a price-to-earnings ratio of 99.95, a P/E/G ratio of 2.64 and a beta of 1.39. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The firm's 50 day simple moving average is $322.10 and its 200 day simple moving average is $316.13.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. During the same quarter last year, the company posted $1.08 EPS. The company's revenue for the quarter was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Are These 5 Undervalued Stocks Ready to Break Out?

Several research firms recently commented on PODD. Oppenheimer upped their price target on shares of Insulet from $324.00 to $365.00 and gave the company an "outperform" rating in a research note on Monday, September 8th. Weiss Ratings reissued a "hold (c)" rating on shares of Insulet in a report on Wednesday, October 8th. Royal Bank Of Canada increased their target price on shares of Insulet from $370.00 to $380.00 and gave the stock an "outperform" rating in a research report on Friday. Jefferies Financial Group raised their target price on shares of Insulet from $375.00 to $400.00 and gave the stock a "buy" rating in a report on Thursday, November 6th. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, Insulet has an average rating of "Moderate Buy" and an average price target of $379.65.

Read Our Latest Analysis on PODD

About Insulet

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Five stocks we like better than Insulet
Stock Sentiment Analysis: How it Works
History Says These are 3 Stocks to Buy for December
What is Insider Trading? What You Can Learn from Insider Trading
Warner Bros. Sale Rumors Heat Up: What Investors Need to Know
Trading Halts Explained
From Science Project to Solvent: WeRide’s 761% Revenue Surge

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Insulet Right Now?

Before you consider Insulet, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.

While Insulet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here